Background: Liraglutide 3 mg was recently approved as an anti-obesity drug. Metformin is weight neutral, yet it\ncould enhance the therapeutic index of GLP-1 agonist. We compared weight-lowering potential of liraglutide 1.\n2 mg in combination with metformin to liraglutide 3 mg monotherapy in obese PCOS.\nMethods: Thirty obese women with PCOS (aged 33.1 Ã?± 6.1 years, BMI 38.3 Ã?± 5.4 kg/m2) were randomized to\ncombination (COMBO) of metformin (MET) 1000 mg BID and liraglutide 1.2 mg QD (N= 15) or liraglutide 3 mg\n(LIRA3) QD alone (N= 15) for 12 weeks. The primary outcome was change in anthropometric measures of obesity.\nResults: Both treatments led to significant weight loss (âË?â??3.6 Ã?± 2.5 kg, p = 0.002 in COMBO vs âË?â??6.3 Ã?± 3.7 kg, p = 0.001\nin LIRA3). BMI and waist circumference reduction in LIRA3 was greater than in COMBO (âË?â??2.2 Ã?± 1.3 vs âË?â??1.3 Ã?± 0.9 kg/\nm2,\np = 0.05 and âË?â??4.2 Ã?± 3.4 vs âË?â??2.2 Ã?± 6.2 cm, p = 0.014, respectively). Both interventions resulted in a significant\ndecrease of post-OGTT glucose levels. COMBO significantly reduced total testosterone and was associated with less\nnausea.\nConclusions: Short-term interventions with COMBO and LIRA3 both led to significant improvement of measures of\nobesity in obese PCOS, LIRA3 being superior to COMBO. However, COMBO further improved androgen profile\nbeyond weight reduction and was associated with better tolerability.
Loading....